ulcerative colitis. Although these drugs are absorbed from the large bowel, it is generally believed that their efficacy is due mainly to the topical application. The concentration of drug reaching the colon depends on formulation factors, the extent of retrograde spreading and the retention time. Foam and suppositories have been shown to be retained mainly in the rectum and sigmoid colon while enema solutions have a great spreading capacity. 7 Because of the high water absorption capacity of the colon, the colonic contents are considerably viscous and their mixing is not efficient, thus availability of most drugs to the absorptive membrane is low. The human colon has over 400 distinct species of bacteria as resident flora, a possible population of up to 1010 bacteria per gram of colonic contents. Among the reactions carried out by these gut flora are azoreduction and enzymatic cleavage i.e. glycosides. 8 These metabolic processes may be responsible for the metabolism of many drugs and may also be applied to colon-targeted delivery of peptide based macromolecules such as insulin by oral administration. 
Advantages of CDDS over Conventional Drug Delivery
Chronic colitis, namely ulcerative colitis, and Crohn' s disease are currently treated with glucocorticoids, and other antiinflammatory agents. 10 Administration of glucocorticoids namely dexamethasone and methyl prednisolone by oral and intravenous routes produce systemic side effects including adenosuppression, immunosuppression, cushinoid symptoms, and bone resorption. 11 Thus selective delivery of drugs to the colon could not only lower the required dose but also reduce the systemic side effects caused by high doses. 12
Criteria for Selection of Drug for CDDS
The best Candidates for CDDS are drugs which show poor absorption from the stomach or intestine including peptides. The Somatropin,Urotoilitin drugs used in the treatment of IBD, ulcerative colitis, diarrhea, and colon cancer are ideal candidates for local colon delivery. 13 The criteria for selection of drugs for CDDS is summarized in Table  2 . [14] [15] [16] Drug Carrier is another factor which influences CDDS. The selection of carrier for particular drugs depends on the physiochemical nature of the drug as well as the disease for which the system is to be used. Factors such as chemical nature, stability and partition coefficient of the drug and type of absorption enhancer chosen influence the carrier selection. Moreover, the choice of drug carrier depends on the functional groups of the drug molecule. 17 For example, aniline or nitro groups on a drug may be used to link it to another benzene group through an azo bond. The carriers, which contain additives like polymers (may be used as matrices and hydro gels or coating agents) may influence the release properties and efficacy of the systems. 13
Approaches used for Site Specific Drug Delivery to Colon (CDDS)
Several approaches are used for site-specific drug delivery. Among the primary approaches for CDDS, These include:
1) Primary Approaches for CDDS a. pH Sensitive Polymer Coated Drug Delivery to the Colon
In the stomach, pH ranges between 1 and 2 during fasting but increases after eating. 18 The pH is about 6.5 in the proximal small intestine, and about 7.5 in the distal small intestine. 19 From the ileum to the colon, pH declines significantly. It is about 6.4 in the cecum. However, pH values as low as 5.7 have been measured in the ascending colon in healthy volunteers. 20 The pH in the transverse colon is 6.6 and 7.0 in the descending colon. Use of pH dependent polymers is based on these differences in pH levels. The polymers described as pH dependent in colon specific drug delivery are insoluble at low pH levels but become increasingly soluble as pH rises. 21 Although a pH dependent polymer can protect a formulation in the stomach, and proximal small intestine, it may start to dissolve in the lower small intestine, and the site-specificity of formulations can be poor. 22 The decline in pH from the end of the small intestine to the colon can also result in problems, lengthy lag times at the ileo-cecal junction or rapid transit through the ascending colon which can also result in poor site-specificity of enteric-coated single-unit formulations. 21 b. Delayed (Time Controlled Release System) Release Drug Delivery to Colon Time controlled release system (TCRS) such as sustained or delayed release dosage forms are also very promising drug release systems. However, due to potentially large variations of gastric emptying time of dosage forms in humans, in these approaches, colon arrival time of dosage forms cannot be accurately predicted, resulting in poor colonical availability. 23 The dosage forms may also be applicable as colon targeting dosage forms by prolonging the lag time of about 5 to 6 h. However, the disadvantages of this system are: i. Gastric emptying time varies markedly between subjects or in a manner dependent on type and amount of food intake. ii. Gastrointestinal movement, especially peristalsis or contraction in the stomach would result in change in gastrointestinal transit of the drug. 24 iii. Accelerated transit through different regions of the colon has been observed in patients with the IBD, the carcinoid syndrome and diarrhea, and the ulcerative colitis. 9, 25, 26 Therefore, time dependent systems are not ideal to deliver drugs to the colon specifically for the treatment of colon related diseases. Appropriate integration of pH sensitive and time release functions into a single dosage form may improve the site specificity of drug delivery to the colon. Since the transit time of dosage forms in the small intestine is less variable i.e. about 3±1 hr. 27 The time-release function (or timer function) should work more efficiently in the small intestine as compared the stomach. In the small intestine drug carrier will be delivered to the target side, and drug release will begin at a predetermined time point after gastric emptying. On the other hand, in the stomach, the drug release should be suppressed by a pH sensing function (acid resistance) in the dosage form, which would reduce variation in gastric residence time. 24 Enteric coated time-release press coated (ETP) tablets, are composed of three components, a drug containing core tablet (rapid release function), the press coated swellable hydrophobic polymer layer (Hydroxy propyl cellulose layer (HPC), time release function) and an enteric coating layer (acid resistance function). 23, 28 The tablet does not release the drug in the stomach due to the acid resistance of the outer enteric coating layer. After gastric emptying, the enteric coating layer rapidly dissolves and the intestinal fluid begins to slowly erode the press coated polymer (HPC) layer. When the erosion front reaches the core tablet, rapid drug release occurs since the erosion process takes a long time as there is no drug release period (lag phase) after gastric emptying.
The duration of lag phase is controlled either by the weight or composition of the polymer (HPC) layer. (Fig. 1) 
c. Microbially Triggered Drug Delivery to Colon
The microflora of the colon is in the range of 1011 -1012 CFU/ mL, consisting mainly of anaerobic bacteria, e.g. bacteroides, bifidobacteria, eubacteria, clostridia, enterococci, enterobacteria and ruminococcus etc. 25 This vast microflora fulfills its energy needs by fermenting various types of substrates that have been left undigested in the small intestine, e.g. di-and tri-saccharides, polysaccharides etc. 29, 30 For this fermentation, the microflora produces a vast number of enzymes like glucoronidase, xylosidase, arabinosidase, galactosidase, nitroreductase, azareducatase, deaminase, and urea dehydroxylase. 31 Because of the presence of the biodegradable enzymes only in the colon, the use of biodegradable polymers for colon-specific drug delivery seems to be a more site-specific approach as compared to other approaches. 5 These polymers shield the drug from the environments of stomach and small intestine, and are able to deliver the drug to the colon. On reaching the colon, they undergo assimilation by micro-organism, or degradation by enzyme or break down of the polymer back bone leading to a subsequent reduction in their molecular weight and thereby loss of mechanical strength. [32] [33] [34] [35] [36] They are then unable to hold the drug entity any longer. 37 i) Prodrug Approach for Drug Delivery to Colon Prodrug is a pharmacologically inactive derivative of a parent drug molecule that requires spontaneous or enzymatic transformation in vivo to release the active drug. For colonic delivery, the prodrug is designed to undergo minimal hydrolysis in the upper tracts of GIT, and undergo enzymatic hydrolysis in the colon there by releasing the active drug moiety from the drug carrier. Metabolism of azo compounds by intestinal bacteria is one of the most extensively Colon Targeted Drug Delivery... Philip et al. studied bacterial metabolic process. 38 A number of other linkages susceptible to bacterial hydrolysis specially in the colon have been prepared where the drug is attached to hydrophobic moieties like amino acids, glucoronic acids, glucose, glactose, cellulose etc. Limitations of the prodrug approach is that it is not a very versatile approach as its formulation depends upon the functional group available on the drug moiety for chemical linkage. Furthermore, prodrugs are new chemical entities, and need a lot of evaluation before being used as carriers. 39 A number of prodrugs have been outlined in Table 3 . In vitro Less hydrolysis of the prodrug was seen in contents of stomach and proximal small intestine (PSI).hydrolysis increased in contents of distal small intestine (DSI) and was maximum in cecal content homogenates. galactosides hydrolyzed faster than glucosides which hydrolyzed faster than the corresponding cellobioside 38 Glucuronide conjugates glucuronic acid Naloxone/nalmefene Glucuronide linkage Rat When given to morphine dependent rats, these reversed the GIT side effects caused by morphine without causing CNS withdrawal symptom because of activation in large intestine followed by a resultant diarrheas which excreted the prodrug 7 drug 46
Budesonide Glucuronide linkage
Rat Was found to be superior than budesonide itself for treatment of colitis 47 (ii) Azo-Polymeric Prodrugs Newer approaches are aimed at the use of polymers as drug carriers for drug delivery to the colon. Both synthetic as well as naturally occurring polymers have been used for this purpose. Sub synthetic polymers have been used to form polymeric prodrug with azo linkage between the polymer and drug moiety. 48 These have been evaluated for CDDS. Various azo polymers have also been evaluated as coating materials over drug cores. These have been found to be similarly susceptible to cleavage by the azoreducatase in the large bowel. Coating of peptide capsules with polymers cross linked with azoaromatic group have been found to protect the drug from digestion in the stomach and small intestine. In the colon, the azo bonds are reduced, and the drug is released. 28 A number of azopolymeric prodrugs are outlined in Table 4 . In basic media enteric coating dissolves and beads swell to exceed the strength of aquacoat film, which then burst releasing the drug 61 iii) Polysaccharide Based Delivery Systems The use of naturally occurring polysaccharides is attracting a lot of attention for drug targeting the colon since these polymers of monosaccharides are found in abundance, have wide availability are inexpensive and are available in a verity of a structures with varied properties. They can be easily modified chemically, biochemically, and are highly stable, safe, nontoxic, hydrophilic and gel forming and in addition, are biodegradable. These include naturally occurring polysaccharides obtained from plant (guar gum, inulin), animal (chitosan, chondrotin sulphate), algal (alginates) or microbial (dextran) origin. The polysaccrides can be broken down by the colonic microflora to simple saccharides. 21 Therefore, they fall into the category of "generally regarded as safe" (GRAS). A number of polysaccharide-based delivery systems have been outlined in Table  5 .
Newly Developed Approaches for CDDS a. Pressure Controlled Drug-Delivery Systems
As a result of peristalsis, higher pressures are encountered in the colon than in the small intestine. Takaya et al. developed pressure controlled colon-delivery capsules prepared using ethylcellulose, which is insoluble in water. 62 In such systems, drug release occurs following the disintegration of a water-insoluble polymer capsule because of pressure in the lumen of the colon. The thickness of the ethylcellulose membrane is the most important factor for the disintegration of the formulation. 63, 64 The system also appeared to depend on capsule size and density. Because of reabsorption of water from the colon, the viscosity of luminal content is higher in the colon than in the small intestine. It has therefore been concluded that drug dissolution in the colon could present a problem in relation to colon-specific oral drug delivery systems. In pressure controlled ethylcellulose single unit capsules the drug is in a liquid. 65 Lag times of three to five hours in relation to drug absorption were noted when pressure-controlled capsules were administered to humans.
b. Novel Colon Targeted Delivery System (CODESTM)
CODESTM is an unique CDDS technology that was designed to avoid the inherent problems associated with pH or time dependent systems. 66, 67 CODESTM is a combined approach of pH dependent and microbially triggered CDDS. It has been developed by utilizing a unique mechanism involving lactulose, which acts as a trigger for site specific drug release in the colon, (Fig. 2) . The system consists of a traditional tablet core containing lactulose, which is over coated with and acid soluble material, Eudragit E, and then subsequently overcoated with an enteric material, Eudragit L. The premise of the technology is that the enteric coating protects the tablet while it is located in the stomach and then dissolves quickly following gastric emptying. The acid soluble material coating then protects the preparation as it passes through the alkaline pH of the small intestine. 68 Once the tablet arrives in the colon, the bacteria enzymetically degrade the polysaccharide (lactulose) into organic acid. This lowers the pH surrounding the system sufficient to effect the dissolution of the acid soluble coating and subsequent drug release. 69 Figure 2 : Schematics of the conceptual design of CODES™
c. Osmotic Controlled Drug Delivery (ORDS-CT)
The OROS-CT (Alza corporation) can be used to target the drug locally to the colon for the treatment of disease or to achieve systemic absorption that is otherwise unattainable. 70 The OROS-CT system can be a single osmotic unit or may incorporate as many as 5-6 push-pull units, each 4 mm in diameter, encapsulated within a hard gelatin capsule, (Fig. 3 ). 71 Each bilayer push pull unit contains an osmotic push layer and a drug layer, both surrounded by a semipermeable membrane. An orifice is drilled through the membrane next to the drug layer. Immediately after the OROS-CT is swallowed, the gelatin capsule containing the push-pull units dissolves. Because of its drug-impermeable enteric coating, each push-pull unit is prevented from absorbing water in the acidic aqueous environment of the stomach, and hence no drug is delivered. As the unit enters the small intestine, the coating dissolves in this higher pH environment (pH >7), water enters the unit, causing the osmotic push compartment to swell, and concomitantly creates a flowable gel in the drug compartment. Swelling of the osmotic push compartment forces drug gel out of the orifice at a rate precisely controlled by the rate of water transport through the semipermeable membrane. For treating ulcerative colitis, each push pull unit is designed with a 3-4 h post gastric delay to prevent drug delivery in the small intestine. Drug release begins when the unit reaches the colon. OROS-CT units can maintain a constant release rate for up to 24 hours in the colon or can deliver drug over a period as short as four hours. Recently, new phase transited systems have come which promise to be a good tool for targeting drugs to the colon. [72] [73] [74] [75] Various in vitro / in vivo evaluation techniques have been developed and proposed to test the performance and stability of CDDS.
Figure 3: Cross-Section of the OROS-CT colon targeted drug delivery system
For in vitro evaluation, not any standardized evaluation technique is available for evaluation of CDDS because an ideal in vitro model should posses the in-vivo conditions of GIT such as pH, volume, stirring, bacteria, enzymes, enzyme activity, and other components of food. Generally, these conditions are influenced by the diet, physical stress, and these factors make it difficult to design a slandered in-vitro model. In vitro models used for CDDS are: a) In vitro dissolution test Dissolution of controlled-release formulations used for colonspecific drug delivery are usually complex, and the dissolution methods described in the USP cannot fully mimic in vivo conditions such as those relating to pH, bacterial environment and mixing forces. 69 Dissolution tests relating to CDDS may be carried out using the conventional basket method. Parallel dissolution studies in different buffers may be undertaken to characterize the behavior of formulations at different pH levels. Dissolution tests of a colonspecific formulation in various media simulating pH conditions and times likely to be encountered at various locations in the gastrointestinal tract have been studied. 76 The media chosen were, for example, pH 1.2 to simulate gastric fluid, pH 6.8 to simulate the jejunal region of the small intestine, and pH 7.2 to simulate the ileum segment. Enteric-coated capsules for CDDS have been investigated in a gradient dissolution study in three buffers. The capsules were tested for two hours at pH 1.2, then one hour at pH 6.8, and finally at pH 7.4. 77 b) In vitro enzymatic tests Incubate carrier drug system in fermenter containing suitable medium for bacteria (strectococcus faccium and B. Ovatus). The amount of drug released at different time intervals are determined. Drug release study is done in buffer medium containing enzymes (ezypectinase, dextranase), or rat or guinea pig or rabbit cecal contents. The amount of drug released in a particular time is determined, which is directly proportional to the rate of degradation of polymer carrier. c) In vivo evaluation A number of animals such as dogs, guinea pigs, rats, and pigs are used to evaluate the delivery of drug to colon because they resemble the anatomic and physiological conditions as well as the microflora of human GIT. While choosing a model for testing a CDDS, relative model for the colonic diseases should also be considered. Guinea pigs are commonly used for experimental IBD model. The distribution of azoreductase and glucouronidase activity in the GIT of rat and rabbit is fairly comparable to that in the human. 78 For rapid evaluation of CDDS, a novel model has been proposed. In this model, the human fetal bowel is transplanted into a subcutaneous tullel on the back of thymic nude mice, which bascularizes within four weeks, matures, and becomes capable of developing of mucosal immune system from the host.
Drug Delivery Index (DDI) and Clinical Evaluation of Colon-Specific Drug Delivery Systems
DDI is a calculated pharmacokinetic parameter, following single or multiple dose of oral colonic prodrugs. DDI is the relative ratio of RCE (Relative colonic tissue exposure to the drug) to RSC (Relative amount of drug in blood i.e. that is relative systemic exposal to the drug). High drug DDI value indicates better colon drug delivery. Absorption of drugs from the colon is monitored by colonoscopy and intubation. Currently, gamma scintigraphy and high frequency capsules are the most preferred techniques employed to evaluate colon drug delivery systems.
Conclusion
The colonic region of the GIT has become an increasingly important site for drug delivery and absorption. CDDS offers considerable therapeutic benefits to patients in terms of both local and systemic treatment. Colon specificity is more likely to be achieved with systems that utilize natural materials that are degraded by colonic bacterial enzymes. Considering the sophistication of colon-specific drug delivery systems, and the uncertainty of current dissolution methods in establishing possible in-vitro/in-vivo correlation, challenges remain for pharmaceutical scientists to develop and validate a dissolution method that incorporates the physiological features of the colon, and yet can be used routinely in an industry setting for the evaluation of CDDS.
